Performance Claims
Performance claims represent specific acceptance criteria tested in clinical validation studies, showing how the device meets performance thresholds.
Filters
| ID | Study | Device | Domain | Indications | User Group | Value Type | Subject | Metric | Value Achieved | Threshold | Global Value | State of Art | Achieved | vs SOTA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LL5 | Plus | Objective severity assessment | Hidradenitis supurativa |
| Absolute | N/A | inter-observer intraclass correlation coefficient (ICC) | 72.70% [0.66, 0.79] | β₯70.00% | 72.70% LL5 | 47.00% [0.32, 0.65] | Achieved | Exceeds SotA | |
| SDP | Plus | Objective severity assessment | Hidradenitis supurativa |
| Absolute | π€ Device | inter-class coefficient correlation variability (ICC) | 10.00% | <15.00% | 10.00% SDP | 10.00% | Achieved | Matches SotA | |
| MRT | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 15.12% | β₯7.00% | 16.22% MRT61I | 6.36% | Achieved | Exceeds SotA |
| 9D7 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 63.06% [0.57, 0.69] | >47.94% | 63.06% 9D7 | N/A | Achieved | N/A |
| ZKC | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 63.06% [0.57, 0.69] | β₯53.96% | 72.50% ZKCYJCME3 | 49.05% [0.46, 0.54] | Achieved | Exceeds SotA |
| 02A | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 18.43% | >6.93% | 18.43% 02A | 6.30% | Achieved | Exceeds SotA |
| 5IT | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 71.04% [0.69, 0.73] | >70.00% | 73.20% 5ITASM5UMS2C | 69.08% [0.63, 0.75] | Achieved | Exceeds SotA |
| ASM | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 71.04% [0.69, 0.73] | >52.61% | 73.20% 5ITASM5UMS2C | N/A | Achieved | N/A |
| X70 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 19.38% | β₯5.06% | 21.86% X70ZGT | 4.60% | Achieved | Exceeds SotA |
| 0ZD | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 75.83% [0.74, 0.77] | β₯70.00% | 75.83% 0ZD | 76.47% [0.73, 0.79] | Achieved | Below SotA |
| MJY | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 75.83% [0.74, 0.77] | >56.45% | 79.87% MJYFEHVFV | N/A | Achieved | N/A |
| O4L | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 17.00% | β₯7.00% | 19.04% O4L6KXAR8 | 6.36% | Achieved | Exceeds SotA |
| GZS | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 61.71% [0.6, 0.63] | β₯47.91% | 70.66% GZS31QCZRF165XFR7X | N/A | Achieved | N/A |
| 31Q | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 61.71% [0.6, 0.63] | β₯46.12% | 70.66% GZS31QCZRF165XFR7X | 41.93% [0.36, 0.47] | Achieved | Exceeds SotA |
| 81T | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 18.43% | β₯14.30% | 18.90% 81T09O7YC | 13.00% | Achieved | Exceeds SotA |
| 37G | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 71.04% [0.68, 0.74] | β₯66.30% | 75.73% 37GHUGJZ1KPM | 66.30% [0.61, 0.71] | Achieved | Exceeds SotA |
| 19H | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 71.04% [0.68, 0.74] | >52.61% | 72.27% 19H2W5 | N/A | Achieved | N/A |
| 0H6 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 19.38% | β₯11.88% | 19.87% 0H6VEF9YX | 10.80% | Achieved | Exceeds SotA |
| H3D | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 75.83% [0.74, 0.77] | β₯70.10% | 81.58% H3DQX8VCNFBJ | 70.10% [0.65, 0.75] | Achieved | Exceeds SotA |
| 0QF | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 75.83% [0.74, 0.77] | >56.45% | 77.70% 0QFN2E | N/A | Achieved | N/A |
| 6FT | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 8.30% | β₯5.83% | 8.79% 6FTO0B | 5.30% | Achieved | Exceeds SotA |
| GU0 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 65.65% [0.64, 0.67] | β₯57.25% | 73.98% GU047JLXJ | N/A | Achieved | N/A |
| 47J | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 65.65% [0.64, 0.67] | β₯61.80% | 73.98% GU047JLXJ | 56.18% [0.5, 0.62] | Achieved | Exceeds SotA |
| W8N | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 9.37% | β₯6.93% | 45.87% W8NA76Q5G | 6.30% | Achieved | Exceeds SotA |
| A76 | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 71.01% [0.66, 0.75] | β₯70.00% | 45.87% W8NA76Q5G | 72.86% [0.69, 0.75] | Achieved | Below SotA |
| CUC | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 71.01% [0.66, 0.75] | >61.64% | 74.17% CUC3GH | N/A | Achieved | N/A |
| R9C | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 10.61% | β₯5.06% | 10.11% R9CN50 | 4.60% | Achieved | Exceeds SotA |
| 9MI | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 73.08% [0.71, 0.75] | β₯77.60% | 77.05% 9MIB4N | 77.60% [0.7, 0.84] | Not Achieved | Below SotA |
| NLW | BI_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 73.08% [0.71, 0.75] | >62.47% | 77.05% NLWYIO | N/A | Achieved | N/A |
| DII | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 26.77% | β₯6.93% | 26.77% DII | 6.30% | Achieved | Exceeds SotA |
| KOQ | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 57.88% [0.56, 0.59] | β₯30.90% | 57.88% KOQ | N/A | Achieved | N/A |
| NK7 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 25.56% | β₯6.93% | 25.56% NK7 | 6.30% | Achieved | Exceeds SotA |
| DR7 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 46.59% [0.41, 0.5] | >21.04% | 46.59% DR7 | N/A | Achieved | N/A |
| 0I1 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 23.50% | β₯5.06% | 23.50% 0I1 | 4.60% | Achieved | Exceeds SotA |
| WAM | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 62.19% [0.61, 0.63] | >38.69% | 62.19% WAM | N/A | Achieved | N/A |
| JBB | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 32.10% | β₯6.93% | 32.10% JBB | 6.30% | Achieved | Exceeds SotA |
| ERK | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 56.44% [0.55, 0.57] | β₯24.34% | 56.44% ERK | N/A | Achieved | N/A |
| 8PG | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 25.21% | β₯14.30% | 25.21% 8PG | 13.00% | Achieved | Exceeds SotA |
| DIK | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 44.55% [0.39, 0.49] | >19.33% | 44.55% DIK | N/A | Achieved | N/A |
| 99Y | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 24.73% | β₯11.88% | 24.73% 99Y | 10.80% | Achieved | Exceeds SotA |
| 8QZ | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 61.36% [0.6, 0.62] | >36.64% | 61.36% 8QZ | N/A | Achieved | N/A |
| 4KO | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 12.97% | β₯5.83% | 12.97% 4KO | 5.30% | Achieved | Exceeds SotA |
| S03 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 61.11% [0.59, 0.63] | β₯48.15% | 61.11% S03 | N/A | Achieved | N/A |
| TG6 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 16.44% | β₯6.93% | 16.44% TG6 | 6.30% | Achieved | Exceeds SotA |
| OR5 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 52.33% [0.45, 0.59] | >35.89% | 52.33% OR5 | N/A | Achieved | N/A |
| Q2D | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 15.41% | β₯5.06% | 15.41% Q2D | 4.60% | Achieved | Exceeds SotA |
| MM8 | BI_2024 | Plus | Diagnostic accuracy | Rare diseases |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 71.08% [0.69, 0.73] | >55.67% | 71.08% MM8 | N/A | Achieved | N/A |
| 3OA | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | (CUS) | 80.00% | β₯75.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 75.00% | Achieved | Exceeds SotA |
| ZGP | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 50.00% | β75.00% | 50.00% ZGP | 75.00% | Not Achieved | Below SotA | |
| RND | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 100.00% | β₯75.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 75.00% | Achieved | Exceeds SotA | |
| P30 | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 100.00% | β₯75.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 75.00% | Achieved | Exceeds SotA | |
| EZ1 | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 83.00% | β₯75.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 75.00% | Achieved | Exceeds SotA | |
| 3BD | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 67.00% | β₯75.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 75.00% | Not Achieved | Below SotA | |
| NVT | COVIDX_EVCDAO_2022 | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | (CUS) | 76.67% | β₯80.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 80.00% | Not Achieved | Below SotA |
| EAC | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | area under the ROC curve (AUC) | 84.20% [0.82, 0.86] | β₯80.00% | 91.99% EACFIQ | 77.80% [0.74, 0.8] | Achieved | Exceeds SotA | |
| 8H5 | Plus | Resource optimisation | Multiple conditions |
| Relative | N/A | increase in the adequacy of referrals | 7.00% | β₯15.00% | 7.00% 8H5 | 24.00% | Not Achieved | Below SotA | |
| VCT | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 80.00% | β₯70.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 70.00% | Achieved | Exceeds SotA | ||
| DX7 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | area under the ROC curve (AUC) | 82.00% [0.67, 0.94] | β₯80.00% | 82.00% DX7 | 77.80% [0.74, 0.8] | Achieved | Exceeds SotA | |
| LU4 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 57.14% [0.33, 0.79] | β₯80.00% | 57.14% LU4 | 76.00% [0.7, 0.82] | Not Achieved | Below SotA | |
| R9P | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 93.53% [0.89, 0.96] | β₯84.00% | 93.53% R9P | 79.00% [0.71, 0.85] | Achieved | Exceeds SotA | |
| 0L2 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | positive predictive value (PPV) | 42.00% [0.23, 0.67] | β₯40.00% | 42.00% 0L2 | N/A | Achieved | N/A | |
| 7ZI | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | negative predictive value (NPV) | 96.00% [0.92, 0.98] | β₯80.00% | 96.00% 7ZI | N/A | Achieved | N/A | |
| D62 | Plus | Adequacy of referrals | Multiple conditions |
| Relative | N/A | 38.00% | β₯15.00% | 38.00% D62 | 14.00% | Achieved | Exceeds SotA | ||
| CST | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 74.00% [0.57, 0.86] | β₯72.93% | 74.00% CST6H0 | 66.30% [0.69, 0.75] | Achieved | Exceeds SotA | |
| 6H0 | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 74.00% [0.69, 0.75] | β₯45.00% | 74.00% CST6H0 | N/A | Achieved | N/A | |
| H4U | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 67.00% [0.59, 0.74] | β₯66.11% | 67.00% H4U04D | 60.10% [0.51, 0.69] | Achieved | Exceeds SotA | |
| 04D | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 67.00% [0.59, 0.74] | β₯47.00% | 67.00% H4U04D | N/A | Achieved | N/A | |
| DCH | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π€ Device | adequacy of referrals during in-person care | 78.60% [0.6, 0.89] | β₯50.00% | 73.10% DCHDZC | N/A | Achieved | N/A | |
| DZC | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π€ Device | adequacy of referrals during in-person care | 67.60% [0.58, 0.76] | β₯38.90% | 73.10% DCHDZC | N/A | Achieved | N/A | |
| LHF | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π€ Device | adequacy of referrals during remote care | 33.00% [0.06, 0.79] | β₯0.00% | 50.00% LHF4BO | N/A | Achieved | N/A | |
| 4BO | Plus | Adequacy of referrals | Multiple conditions |
| Absolute | π€ Device | adequacy of referrals during remote care | 67.00% [0.52, 0.79] | β₯67.00% | 50.00% LHF4BO | N/A | Achieved | N/A | |
| KPQ | Plus | Resource optimisation | Multiple conditions |
| Relative | N/A | reduction in the number of days | 84.37% | >78.10% | 84.37% KPQ | 71.00% | Achieved | Exceeds SotA | |
| 1M1 | Plus | Resource optimisation | Multiple conditions |
| Relative | N/A | reduction in the number of days | 56.00% | β₯30.00% | 56.00% 1M1 | 71.00% | Achieved | Below SotA | |
| UGS | Plus | Resource optimisation | Multiple conditions |
| Relative | N/A | reduction in the number of days | 5 days | <10.35 | 500.00% UGS | 11.5 days | Achieved | Exceeds SotA | |
| LXJ | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 82.14% [0.64, 0.95] | β₯61.80% | 73.98% GU047JLXJ | 56.18% [0.5, 0.62] | Achieved | Exceeds SotA |
| KW3 | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π€ Device | top-1 accuracy | 78.57% [0.69, 0.86] | β₯50.00% | 70.56% KW3WGP | 50.70% [0.43, 0.57] | Achieved | Exceeds SotA |
| 7V9 | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-3 accuracy | 89.29% [0.75, 1] | β₯60.00% | 89.29% 7V9 | 64.00% [0.57, 0.71] | Achieved | Exceeds SotA |
| 1S5 | IDEI_2023 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-5 accuracy | 89.29% [0.75, 1] | β₯80.00% | 89.29% 1S5 | 80.00% [0.73, 0.87] | Achieved | Exceeds SotA |
| FIQ | IDEI_2023 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | area under the ROC curve (AUC) | 97.00% [0.89, 1] | β₯80.00% | 91.99% EACFIQ | 77.80% [0.74, 0.8] | Achieved | Exceeds SotA |
| GS5 | IDEI_2023 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 87.50% [0.54, 1] | β₯80.00% | 87.50% GS5 | 76.00% [0.7, 0.82] | Achieved | Exceeds SotA |
| 6EP | IDEI_2023 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 97.06% [0.9, 1] | β₯84.00% | 97.06% 6EP | 79.00% [0.71, 0.85] | Achieved | Exceeds SotA |
| PZD | IDEI_2023 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | positive predictive value (PPV) | 87.50% [0.54, 1] | β₯80.00% | 87.50% PZD | N/A | Achieved | N/A |
| V2U | IDEI_2023 | Plus | Detection | Multiple malignant conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | negative predictive value (NPV) | 97.06% [0.89, 1] | β₯95.00% | 97.06% V2U | N/A | Achieved | N/A |
| JWQ | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia |
| Absolute | π€ Device | correlation | 77.00% [0.69, 0.85] | β₯50.00% | 59.00% JWQ2847TS | 60.00% [0.6, 0.8] | Achieved | Exceeds SotA |
| A1Q | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia |
| Absolute | π€ Device | unweighted Kappa | 73.97% [0.65, 0.82] | β₯60.00% | 53.47% A1Q3OB | 60.00% [0.6, 0.8] | Achieved | Exceeds SotA |
| 284 | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia |
| Absolute | π€ Device | correlation | 47.00% [0.39, 0.55] | β₯50.00% | 59.00% JWQ2847TS | 60.00% [0.6, 0.8] | Not Achieved | Below SotA |
| 3OB | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia |
| Absolute | π€ Device | unweighted Kappa | 32.97% [0.26, 0.39] | β₯60.00% | 53.47% A1Q3OB | 60.00% [0.6, 0.8] | Not Achieved | Below SotA |
| 7TS | IDEI_2023 | Plus | Objective severity assessment | Androgenetic alopecia |
| Absolute | π€ Device | correlation | 53.00% [0.45, 0.61] | β₯50.00% | 59.00% JWQ2847TS | 60.00% [0.6, 0.8] | Achieved | Below SotA |
| WGP | Legacy | Diagnostic accuracy | Multiple conditions |
| Absolute | π€ Device | top-1 accuracy | 55.00% [0.45, 0.65] | β₯50.00% | 70.56% KW3WGP | 50.70% [0.43, 0.57] | Achieved | Exceeds SotA | |
| 6R7 | Legacy | Diagnostic accuracy | Multiple conditions |
| Absolute | π€ Device | top-3 accuracy | 75.69% [0.67, 0.83] | β₯60.00% | 75.69% 6R7 | 64.00% [0.57, 0.71] | Achieved | Exceeds SotA | |
| EYP | Legacy | Diagnostic accuracy | Multiple conditions |
| Absolute | π€ Device | top-5 accuracy | 84.22% [0.76, 0.9] | β₯80.00% | 84.22% EYP | 80.00% [0.73, 0.87] | Achieved | Exceeds SotA | |
| 6U1 | Legacy | Detection | Melanoma |
| Absolute | π€ Device | area under the ROC curve (AUC) | 85.00% [0.7629, 0.9222] | β₯80.00% | 85.00% 6U1 | 81.00% [0.78, 0.84] | Achieved | Exceeds SotA | |
| JFM | Legacy | Detection | Melanoma |
| Absolute | π€ Device | top-1 accuracy | 81.00% [0.65, 0.94] | β₯80.00% | 81.00% JFM | 75.40% [0.7, 0.8] | Achieved | Exceeds SotA | |
| ZM8 | Legacy | Detection | Melanoma |
| Absolute | π€ Device | sensitivity | 93.00% [0.88, 0.98] | β₯80.00% | 93.00% ZM8 | 73.40% [0.67, 0.79] | Achieved | Exceeds SotA | |
| 4JY | Legacy | Detection | Melanoma |
| Absolute | π€ Device | specificity | 80.00% [0.69, 0.92] | β₯70.00% | 80.00% 4JY | 76.20% [0.68, 0.84] | Achieved | Exceeds SotA | |
| 9OD | Legacy | Detection | Multiple malignant conditions |
| Absolute | π€ Device | area under the ROC curve (AUC) | 89.83% [0.84, 0.94] | β₯80.00% | 89.83% 9OD | 77.80% [0.74, 0.8] | Achieved | Exceeds SotA | |
| BRI | Legacy | Detection | Multiple malignant conditions |
| Absolute | π€ Device | sensitivity | 81.00% [0.72, 0.88] | β₯80.00% | 81.00% BRI | 76.00% [0.7, 0.82] | Achieved | Exceeds SotA | |
| VFY | Legacy | Detection | Multiple malignant conditions |
| Absolute | π€ Device | specificity | 86.00% [0.77, 0.94] | β₯84.00% | 86.00% VFY | 79.00% [0.71, 0.85] | Achieved | Exceeds SotA | |
| 9G4 | Legacy | Detection | Multiple malignant conditions |
| Absolute | π€ Device | positive predictive value (PPV) | 92.47% [0.85, 0.97] | β₯80.00% | 92.47% 9G4 | N/A | Achieved | N/A | |
| Z96 | Legacy | Detection | Multiple malignant conditions |
| Absolute | π€ Device | negative predictive value (NPV) | 67.89% [0.54, 0.81] | β₯90.00% | 67.89% Z96 | N/A | Not Achieved | N/A | |
| 6KX | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 18.15% | β₯7.00% | 19.04% O4L6KXAR8 | 6.36% | Achieved | Exceeds SotA |
| CZR | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 81.85% [0.8, 0.83] | β₯63.70% | 70.66% GZS31QCZRF165XFR7X | N/A | Achieved | N/A |
| F16 | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 81.85% [0.8, 0.83] | β₯46.12% | 70.66% GZS31QCZRF165XFR7X | 41.93% [0.36, 0.47] | Achieved | Exceeds SotA |
| 09O | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 14.60% | β₯14.30% | 18.90% 81T09O7YC | 13.00% | Achieved | Exceeds SotA |
| HUG | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 83.15% [0.78, 0.87] | β₯72.93% | 75.73% 37GHUGJZ1KPM | 66.30% [0.61, 0.71] | Achieved | Exceeds SotA |
| JZ1 | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 83.15% [0.78, 0.87] | β₯68.55% | 75.73% 37GHUGJZ1KPM | N/A | Achieved | N/A |
| VEF | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 11.90% | β₯11.88% | 19.87% 0H6VEF9YX | 10.80% | Achieved | Exceeds SotA |
| QX8 | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 89.91% [0.88, 0.91] | β₯77.11% | 81.58% H3DQX8VCNFBJ | 70.10% [0.65, 0.75] | Achieved | Exceeds SotA |
| VCN | PH_2024 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 89.91% [0.65, 0.75] | β₯78.01% | 81.58% H3DQX8VCNFBJ | N/A | Achieved | N/A |
| I7Y | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 16.66% | β₯6.93% | 16.66% I7Y | 6.30% | Achieved | Exceeds SotA |
| Z90 | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 22.22% [0.17, 0.27] | β₯5.56% | 22.22% Z90 | N/A | Achieved | N/A |
| 6YW | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 22.22% | β₯14.30% | 22.22% 6YW | 13.00% | Achieved | Exceeds SotA |
| REV | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 44.44% [0.22, 0.66] | >22.22% | 44.44% REV | N/A | Achieved | N/A |
| 5W2 | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 51.85% | β₯11.88% | 51.85% 5W2 | 10.80% | Achieved | Exceeds SotA |
| CH0 | PH_2024 | Plus | Diagnostic accuracy | Rare diseases, Pustular psoriasis |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 74.07% [0.68, 0.79] | >22.22% | 74.07% CH0 | N/A | Achieved | N/A |
| IP4 | PH_2024 | Plus | Resource optimisation | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | reduction in the number of days | 60.70% | β₯40.00% | 60.70% IP4 | 55.00% | Achieved | Exceeds SotA |
| WOI | PH_2024 | Plus | Resource optimisation | Multiple conditions |
| Relative | N/A | increase in patients that can be managed remotely | 49.00% | β₯40.00% | 49.00% WOI | 55.00% | Achieved | Below SotA |
| 61I | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 20.00% | β₯7.00% | 16.22% MRT61I | 6.36% | Achieved | Exceeds SotA | |
| YJC | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 88.78% [0.86, 0.9] | β₯53.96% | 72.50% ZKCYJCME3 | 49.05% [0.46, 0.54] | Achieved | Exceeds SotA | |
| ME3 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 88.78% | β₯68.08% | 72.50% ZKCYJCME3 | N/A | Achieved | N/A | |
| A84 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 28.03% | β₯6.93% | 28.03% A84 | 6.30% | Achieved | Exceeds SotA | |
| 5UM | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 80.64% [0.75, 0.85] | >75.99% | 73.20% 5ITASM5UMS2C | 69.08% [0.63, 0.75] | Achieved | Exceeds SotA | |
| S2C | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 80.64% [0.75, 0.85] | >52.61% | 73.20% 5ITASM5UMS2C | N/A | Achieved | N/A | |
| ZGT | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 30.39% | β₯5.06% | 21.86% X70ZGT | 4.60% | Achieved | Exceeds SotA | |
| FEH | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 86.84% [0.85, 0.88] | >84.12% | 79.87% MJYFEHVFV | 76.47% [0.73, 0.79] | Achieved | Exceeds SotA | |
| VFV | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 86.84% [0.85, 0.88] | >56.45% | 79.87% MJYFEHVFV | N/A | Achieved | N/A | |
| AR8 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 27.00% | β₯7.00% | 19.04% O4L6KXAR8 | 6.36% | Achieved | Exceeds SotA | |
| 5XF | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 89.92% [0.87, 0.91] | β₯46.12% | 70.66% GZS31QCZRF165XFR7X | 41.93% [0.36, 0.47] | Achieved | Exceeds SotA | |
| R7X | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 89.92% [0.87, 0.91] | β₯62.90% | 70.66% GZS31QCZRF165XFR7X | N/A | Achieved | N/A | |
| 7YC | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 24.95% | β₯14.30% | 18.90% 81T09O7YC | 13.00% | Achieved | Exceeds SotA | |
| KPM | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 76.53% [0.7, 0.83] | β₯72.93% | 75.73% 37GHUGJZ1KPM | 66.30% [0.61, 0.71] | Achieved | Exceeds SotA | |
| 2W5 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 76.53% [0.7, 0.83] | >51.58% | 72.27% 19H2W5 | N/A | Achieved | N/A | |
| 9YX | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 29.80% | β₯11.88% | 19.87% 0H6VEF9YX | 10.80% | Achieved | Exceeds SotA | |
| FBJ | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 84.15% [0.82, 0.86] | β₯77.11% | 81.58% H3DQX8VCNFBJ | 70.10% [0.65, 0.75] | Achieved | Exceeds SotA | |
| N2E | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 84.15% [0.82, 0.86] | >54.35% | 77.70% 0QFN2E | N/A | Achieved | N/A | |
| O0B | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 10.50% | β₯5.00% | 8.79% 6FTO0B | 5.00% | Achieved | Exceeds SotA | |
| 8V3 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 86.93% [0.85, 0.89] | >61.80% | 86.93% 8V3UC7 | 56.18% [0.5, 0.62] | Achieved | Exceeds SotA | |
| UC7 | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | top-1 accuracy | 86.93% [0.85, 0.89] | >76.47% | 86.93% 8V3UC7 | N/A | Achieved | N/A | |
| BHO | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 14.70% | β₯6.93% | 14.70% BHO | 6.30% | Achieved | Exceeds SotA | |
| Q5G | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 85.08% [0.75, 0.92] | β₯82.80% | 45.87% W8NA76Q5G | 72.86% [0.69, 0.75] | Achieved | Exceeds SotA | |
| 3GH | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | sensitivity | 85.08% [0.75, 0.92] | >70.38% | 74.17% CUC3GH | N/A | Achieved | N/A | |
| N50 | Plus | Diagnostic accuracy | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | specificity | 8.37% | β₯5.06% | 10.11% R9CN50 | 4.60% | Achieved | Exceeds SotA | |
| B4N | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 90.72% [0.88, 0.93] | β₯85.36% | 77.05% 9MIB4N | 77.60% [0.7, 0.84] | Achieved | Exceeds SotA | |
| YIO | Plus | Diagnostic accuracy | Multiple conditions |
| Absolute | π©ββοΈ HCP + π¦Ύ Device | specificity | 90.72% [0.88, 0.93] | >82.35% | 77.05% NLWYIO | N/A | Achieved | N/A | |
| V2J | Plus | Resource optimisation | Multiple conditions |
| Relative | π©ββοΈ HCP + π¦Ύ Device | reduction in the number of days | 42.00% | <76.00% | 42.00% V2J | 24.00% | Achieved | Below SotA | |
| WL4 | Plus | Resource optimisation | Multiple conditions |
| Relative | N/A | increase in patients that can be managed remotely | 56.00% | β₯40.00% | 56.00% WL4 | 55.00% | Achieved | Exceeds SotA | |
| LYP | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 87.00% | <75.00% | 87.00% LYP | 70.00% | Not Achieved | Below SotA | ||
| 8MV | Plus | Delphi-based consensus | Multiple conditions |
| Absolute | N/A | 100.00% | β₯75.00% | 84.33% 3OARNDP30EZ13BDNVTVCT8MV | 70.00% | Achieved | Exceeds SotA |
Performance Claim Statements
The device enables better objective severity assessment of hidradenitis supurativa with a inter-observer intraclass correlation coefficient (ICC) value of 72.70% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of hidradenitis supurativa with a inter-class coefficient correlation variability (ICC) value of 10.00% which is lower than the state of the art, based on expert assessment.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 15.12% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 63.06% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 63.06% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 18.43% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 19.38% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 17.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 61.71% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 61.71% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 18.43% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.04% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 19.38% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 75.83% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 8.30% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 65.65% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 65.65% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 9.37% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.01% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 71.01% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 10.61% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 73.08% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 73.08% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 26.77% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 57.88% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 25.56% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 46.59% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 23.50% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 62.19% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 32.10% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 56.44% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 25.21% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 44.55% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 24.73% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 61.36% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 12.97% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a top-1 accuracy value of 61.11% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 16.44% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a sensitivity value of 52.33% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 15.41% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases with a specificity value of 71.08% which is greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null (CUS) value of 80.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 50.00% which is between range the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 100.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 100.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 83.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 67.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null (CUS) value of 76.67% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 84.20% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a increase in the adequacy of referrals value of 7.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 80.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 82.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a sensitivity value of 57.14% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a specificity value of 93.53% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 42.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a negative predictive value (NPV) value of 96.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a null value of 38.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a sensitivity value of 74.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a sensitivity value of 74.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a specificity value of 67.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a specificity value of 67.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during in-person care value of 78.60% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during in-person care value of 67.60% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during remote care value of 33.00% which is equal to or greater than the state of the art.
The device enables better adequacy of referrals of multiple conditions with a adequacy of referrals during remote care value of 67.00% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 84.37% which is greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 56.00% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 5 days which is lower than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 82.14% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 78.57% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-3 accuracy value of 89.29% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-5 accuracy value of 89.29% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 97.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a sensitivity value of 87.50% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a specificity value of 97.06% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 87.50% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a negative predictive value (NPV) value of 97.06% which is equal to or greater than the state of the art.
The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 77.00% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a unweighted Kappa value of 73.97% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 47.00% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a unweighted Kappa value of 32.97% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better objective severity assessment of androgenetic alopecia with a correlation value of 53.00% which is equal to or greater than the state of the art, based on expert assessment.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 55.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-3 accuracy value of 75.69% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-5 accuracy value of 84.22% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a area under the ROC curve (AUC) value of 85.00% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a top-1 accuracy value of 81.00% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a sensitivity value of 93.00% which is equal to or greater than the state of the art.
The device enables better detection of melanoma with a specificity value of 80.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a area under the ROC curve (AUC) value of 89.83% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a sensitivity value of 81.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a specificity value of 86.00% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a positive predictive value (PPV) value of 92.47% which is equal to or greater than the state of the art.
The device enables better detection of multiple malignant conditions with a negative predictive value (NPV) value of 67.89% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 18.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 81.85% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 81.85% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 14.60% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 83.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 83.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 11.90% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 89.91% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 89.91% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a top-1 accuracy value of 16.66% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a top-1 accuracy value of 22.22% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a sensitivity value of 22.22% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a sensitivity value of 44.44% which is greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a specificity value of 51.85% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of rare diseases, pustular psoriasis with a specificity value of 74.07% which is greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 60.70% which is equal to or greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a increase in patients that can be managed remotely value of 49.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 20.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 88.78% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 88.78% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 28.03% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 80.64% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 80.64% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 30.39% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 86.84% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 86.84% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 27.00% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 89.92% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 89.92% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 24.95% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 76.53% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 76.53% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 29.80% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 84.15% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 84.15% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 10.50% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 86.93% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a top-1 accuracy value of 86.93% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 14.70% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 85.08% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a sensitivity value of 85.08% which is greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 8.37% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 90.72% which is equal to or greater than the state of the art.
The device enables better diagnostic accuracy of multiple conditions with a specificity value of 90.72% which is greater than the state of the art.
The device enables better resource optimisation of multiple conditions with a reduction in the number of days value of 42.00% which is lower than the state of the art.
The device enables better resource optimisation of multiple conditions with a increase in patients that can be managed remotely value of 56.00% which is equal to or greater than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 87.00% which is lower than the state of the art.
The device enables better delphi-based consensus of multiple conditions with a null value of 100.00% which is equal to or greater than the state of the art.


